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Abstract 21 
Microwells fabricated from poly-L-lactic acid (PLLA) were evaluated for their application as an oral drug delivery 22 
system using the amorphous sodium salt of furosemide (ASSF) as a model drug. Hot embossing of PLLA resulted in 23 
fabrication of microwells with an inner diameter of 240 µm and a height of 100 µm. The microwells were filled with 24 
ASSF using a modified screen printing technique, followed by coating of the microwell cavities with a gastro-resistant 25 
lid of Eudragit® L100. The release behavior of ASSF from the coated microwells was investigated using a µ-Diss 26 
profiler and a UV imaging system, and under conditions simulating the changing environment of the gastrointestinal 27 
tract. Biorelevant gastric medium (pH 1.6) was employed, after which a change to biorelevant intestinal release medium 28 
(pH 6.5) was carried out. Both µ-Diss profiler and UV imaging release experiments showed that sealing of microwell 29 
cavities with an Eudragit® layer prevented drug release in biorelevant gastric medium. An immediate release of the 30 
ASSF from coated microwells was observed in the intestinal medium. This pH-triggered release behavior demonstrates 31 
the future potential of PLLA microwells as a site-specific oral drug delivery system.  32 
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1 Introduction 33 
The oral route is widely considered as the preferred administration method for drug delivery, due to its non-invasive 34 
nature and the possibility for self-administration, which together provide a high patient compliance as well as an 35 
improved safety compared to other administration routes (Balimane et al. 2000; Perioli et al. 2012). However, an 36 
increasing number of new drug compounds exhibit poor aqueous solubility, a slow rate of dissolution and/or poor 37 
intestinal permeability, making effective oral drug delivery  increasingly challenging (Bergstrom et al. 2007; Newman 38 
et al. 2008). Innovative drug delivery systems have the potential to facilitate an improvement in oral bioavailability 39 
compared to current drug formulations. Novel approaches such as mucoadhesive gastrointestinal (GI) patches and micro 40 
fabricated devices have been suggested as oral delivery systems for drug compounds (Chirra and Desai 2012; Colombo 41 
et al. 2009; Eaimtrakarn et al. 2001). In particular, microfabricated wells have been proposed as promising oral drug 42 
delivery systems (Ahmed et al. 2002; Ainslie et al. 2009; Tao et al. 2003). These microwells are small structures 43 
consisting of a walled reservoir (into which drug can be incorporated) extending from a flat base. The size and shape of 44 
these microwells can easily be controlled to maximize the contact area with absorptive tissues, such as the intestinal 45 
membrane, providing optimal conditions for drug absorption. Furthermore, in comparison to micro- and nanoparticles, 46 
only one side of microwells is exposed to the external environment. This allows for unidirectional drug release, and also 47 
for protection of the drug in harsh environments, such as that occurring in the stomach (Ahmed et al. 2002; Ainslie et al. 48 
2009; Eaimtrakarn et al. 2001; Tao et al. 2003). Microwells have previously been fabricated using various materials, 49 
including silicon (Ahmed et al. 2002), poly(methyl methacrylate) (Chirra and Desai 2012; Tao and Desai 2005) and SU-50 
8 (Tao and Desai 2007). The authors have previously presented processes for fabrication of microstructured wells using 51 
the polymers polycaprolactone (PCL) and poly-L-lactic acid (PLLA) (Nagstrup et al. 2011). These materials are 52 
advantageous as they are already used in other medical devices approved by the US Food and Drug Administration.  53 
 54 
The increasing level of difficulty associated with oral delivery of new as well as established drug candidates is 55 
exemplified by furosemide, a Biopharmaceutics Classification System class IV compound with both a poor aqueous 56 
solubility and a low intestinal permeability. Furosemide is a loop-diuretic and is mainly used for oral treatment of 57 
hypertension and oedema (Matsuda et al. 1990). The employment of an amorphous sodium salt of furosemide (ASSF) 58 
has been previously shown to significantly improve aqueous solubility and dissolution rate in comparison to furosemide 59 
in a crystalline acid form (Nielsen et al. 2013a). However, while the employment of ASSF may aid in countering 60 
solubility and dissolution-related issues, the poor intestinal absorption of furosemide is further complicated by a 61 
tendency to undergo site-specific absorption partly in the stomach, but especially in the upper part of the small intestine, 62 
leading to a considerable inter- and intra-individual variation in oral drug bioavailability (20-60%) (Iannuccelli et al. 63 
2000). There is therefore, a further need to improve furosemide absorption and specifically reduce the variation in 64 
bioavailability, a task which could be accomplished through the use of advanced drug delivery systems, such as 65 
microwells.  66 
 67 
Typically, drug is filled into microwells using techniques such as microspotting and injection, which allow for loading 68 
of nanoliter quantities of solution into the reservoirs (Ahmed et al. 2002). Following filling, particularly when 69 
consideration of oral delivery, it may be desirable to seal the open side of the filled microwells with a lid in order to 70 
allow for an even greater degree of drug protection during transit prior to arrival at the site of absorption, and also to 71 
provide a level of control over the rate and/or location at which the drug is released. In this respect, Eudragit® polymers 72 
have been successfully employed in many studies as biocompatible coatings for oral dosage forms. Eudragit® polymers 73 
can be utilized to facilitate a slower drug release, which may lead to an enhancement of drug absorption and a 74 
prolonged drug effect (Pandey et al. 2013). They may also be used in order to facilitate controlled drug release in 75 
selected areas of the GI tract (Luppi et al. 2009; Zhu et al. 2011). Eudragit® L100 in particular is a pH-sensitive anionic 76 
copolymer based on methacrylic acid and methyl methacrylate, which dissolves at pH levels higher than 6. Coating of 77 
dosage forms with Eudragit® L100 has been shown to be a very useful strategy for protecting orally-delivered drugs 78 
from the acidic environment of the stomach. Subsequent, dissolution of Eudragit® L100 upon encountering the higher 79 
pH of the small intestine then allows for drug exposure and absorption (Pandey et al. 2013).  80 
 81 
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The studies presented to date in the literature demonstrate initial investigations in the employment of microwells as drug 82 
delivery systems (Ahmed et al. 2002; Ainslie et al. 2009; Tao et al. 2003). The current work therefore aims to contribute 83 
to the body of work concerned with optimization of microfabricated devices for oral drug delivery, by first investigating 84 
their potential to be loaded with ASSF as a model drug, and furthermore by determining their ability to protect and 85 
deliver ASSF under conditions approximating those found in the GI tract. To the best of the authors’ knowledge, this is 86 
the first time micro- fabricated drug delivery devices have been combined with biopolymers and pH- dependent enteric 87 
coatings. The biodegradable microwells fabricated from PLLA were filled with ASSF using an innovative stencil-based 88 
method depositing the powder drug into the microwells. Filled microwells were then spray coated with a lid of 89 
Eudragit® L100. The release of ASSF from coated microwells was investigated in gastric and intestinal biorelevant 90 
media using a µ-Diss profiler and a UV-imaging system, in order to investigate the ability of the Eudragit® coating to 91 
facilitate drug protection and controlled release and to determine the suitability of the microwells as oral delivery 92 
systems.    93 
 94 
2 Materials and Methods 95 
2.1 Materials 96 
PLLA granulate 2002D was obtained from Nature Works LLC (Blair, USA). Furosemide (˃98% purity) and 97 
taurocholic acid sodium salt hydrate (sodium taurocholate) were purchased from Sigma-Aldrich (St. Louis, MO, USA). 98 
Eudragit® L100 was obtained from Evonik Industries (Darmstadt, Germany). Phosphatidylcholine (Lipoid S PC, purity 99 
≥ 98% phosphatidylcholine) was obtained from Lipoid AG (Ludwigshafen, Germany). Sodium azide, sodium chloride 100 
and potassium dihydrogen phosphate were acquired from Merck (Darmstadt, Germany). Ultra-purified water was 101 
obtained from an SG Ultra Clear water system (SG Water USA, LLC, Nashua, NH, USA) and was freshly produced in 102 
all cases. All other chemicals used were of analytical grade.  103 
 104 
2.2 Methods 105 
2.2.1 Fabrication of PLLA microwells by hot embossing 106 
The microwells were prepared by hot embossing in PLLA films in a similar manner to shown previously (Nagstrup et 107 
al. 2011).  Briefly, a PLLA solution (Nature Works LLC, 2002D, 25 wt% in dichloromethane) was first manually 108 
dispensed onto a 4-inch silicon wafer. Using a spin coating process, the wafer was accelerated to a final spin speed of 109 
500 rpm which was maintained for 50 s in order to obtain a uniform PLLA film. Produced PLLA films were then 110 
degassed for 2 h and baked at 220°C for 1 h. The film thickness was measured using a contact profilometer (Dektak8, 111 
Veeco, Mannheim, Germany) and the films with a thickness of 100-110 µm were further used for fabrication of the 112 
PLLA microwells. For this purpose, a nickel stamp was prepared by electroplating. The stamp and the PLLA coated 113 
wafers were brought in contact in a hot embossing system (EV Group 520, St. Florian am Inn, Austria) and heated to 114 
120°C with a temperature ramping of 10°C/min. A pressure of 1.9 MPa was applied to emboss the stamp into the 115 
polymer. After 1 h the assembly was cooled down to room temperature, the pressure was released and the stamp was 116 
removed from the polymer. Following hot embossing, the wafers containing PLLA microwells were cut into chips of 117 
12.8 x 12.8 mm2.  118 
 119 
2.2.2 Preparation and manufacturing of ASSF  120 
Amorphous sodium salt of furosemide (ASSF) was prepared as described earlier (Nielsen et al. 2013a). Briefly, purified 121 
water and ethanol (96%) were mixed in a ratio of 10:1 v/v, and crystalline furosemide acid was added at a concentration 122 
of 0.4 w/v%, together with 5 M NaOH in a molar ratio of 1:1 with furosemide. The resulting solution was spray dried in 123 
a Büchi Mini Spray-Dryer B-290 (Büchi Labortechnik AG, Flawil, Switzerland). Following completion of the process, 124 
the spray dried ASSF was collected and stored in glass vials protected from light. X-ray powder diffraction (XRPD) 125 
analysis was performed after spray drying to confirm formation of ASSF.  126 
 127 
2.2.3 Filling of microwells with ASSF 128 
A simple version of a screen printing technique was applied in order to fill the PLLA microwells with ASSF, as shown 129 
in Fig 1. A stencil mask was first fabricated from transparent foil by laser machining using a CO2 laser (48-5S Duo 130 
Lase, Synrad Inc., USA). The stencil was designed to exhibit holes in a position and of a diameter matching the 131 
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fabricated microwells with a high level of precision (variation in position/diameter in the low µm range). The stencil 132 
was aligned with the microwells using an optical microscope (Fig 1, step 1) and brought in close contact. ASSF powder 133 
was then pressed through the stencil (Fig 1, steps 2 and 3), and into the microwells. Finally, the stencil was removed, 134 
effectively removing any excess ASSF powder not located within the microwells (Fig 1, step 4). 135 
 136 
2.2.4 Coating of drug-filled microwells with Eudragit® L100 137 
A spray coating system (ExactaCoat, Sono Tek, USA) equipped with an ultrasonic nozzle actuated at 120 kHz (Keller 138 
et al. 2013) was used to deposit Eudragit® L100 (dissolved to a 1 wt% solution in isopropyl alcohol) on the cavity of the 139 
drug-filled microwells. The generator power was set to 1.5 W, and the polymer solution was pumped through the nozzle 140 
at a flow rate of 100 µL/min. Nitrogen gas at a pressure of 10 mbar was used to direct the beam of droplets onto the 141 
microwells. The distance between nozzle and substrate was 40 mm, and the beam diameter on the substrate was 142 
approximately 4 mm. The lateral movements of the nozzle were controlled by an x-y stage and the nozzle path was 143 
defined in the equipment software. The nozzle was moved line-by-line at a speed of 25 mm/s, and the coating was 144 
repeated 60 times to obtain a coating thickness in the µm range. Following the coating procedure, microwells were 145 
analyzed by scanning electron microscopy (SEM) with a Nova 600 NanoSEM (FEI, The Netherlands). 146 
 147 
2.2.5 Preparation of simulated gastric and intestinal media 148 
A biorelevant medium simulating the composition of fasted state gastric fluid was prepared in accordance with Vertzoni 149 
et al. (Vertzoni et al. 2005). The required volume of a stock solution of phosphatidylcholine in chloroform (20 µM) was 150 
subjected to a steady stream of nitrogen in order to evaporate the solvent and form a lipid film. 80 µM of sodium 151 
taurocholate was then weighed and added to the lipid film, together with 90 mL of 0.02 M HCl solution. A separate 152 
solution containing 80 mL of 0.02 M HCl, 0.1 mg/mL pepsin and 120.7 mOsm/kg sodium chloride was also prepared. 153 
Following overnight stirring, the solutions were mixed, diluted with 700 mL of 0.02 M HCl, adjusted to a pH of 1.6 and 154 
made to volume (1 L) with purified water.  155 
 156 
A medium simulating the conditions of the fasted intestine was also prepared, as described previously (Nielsen et al. 157 
2013a). The medium utilized for the current studies contained 5 mM of sodium taurocholate as a bile salt and 1.25 mM 158 
of phosphatidylcholine as a phospholipid. The required volume of phosphatidylcholine in chloroform was first exposed 159 
to a flow of nitrogen, resulting in the formation of a lipid film.  The volume of a phosphate buffer/sodium azide stock 160 
solution required to give a concentration of 100/3 mM was then added, together with a quantity of sodium chloride 161 
stock solution necessary to achieve a constant osmolarity of 270 mOsm. The medium was stirred overnight at 37°C, 162 
following which the pH was adjusted to 6.5 and the medium was made to volume with purified water. 163 
 164 
2.2.6 Characterization of ASSF release from Eudragit® L100-coated microwells: µ-Diss profiler 165 
The release of ASSF from Eudragit®-coated micro wells was investigated in conditions simulating those of the GI tract 166 
using a µ-Diss profiler (pION INC, Woburn, MA). Release studies were performed in biorelevant gastric medium for 167 
120 min, followed by a switch to biorelevant intestinal medium for a further 180 min. Before each release experiment, a 168 
standard curve was constructed in each channel of the apparatus in each medium, using in situ UV probes with a path 169 
length of 5 mm. In order to prepare standard curves, aliquots of a stock solution of furosemide (in water adjusted to pH 170 
10 with NaOH) were added to medium, and the resulting UV spectrum of the solution was measured. The process of 171 
addition of aliquots followed by spectral measurement was repeated 8 times in order to produce standard curves 172 
covering the entire linear absorbance range. For the release experiments themselves, 12.8 x 12.8 mm2 chips containing 173 
400 microwells (weighed before and after drug filling in order to allow for accurate determination of the weight of 174 
contained ASSF) were attached to the cylindrical magnetic stirring bar of µ-Diss vials. The microwell chips were 175 
covered with 10 mL of biorelevant medium, and spectral collection was initiated. Release experiments in both gastric 176 
and intestinal medium were run at 37°C with a stirring rate of 100 rpm, and recorded spectra were analyzed in the 177 
wavelength range 310-350 nm. Experiments were performed in triplicate and data are presented as mean ± standard 178 
deviation (SD). 179 
 180 
2.2.7 Characterization of ASSF release from Eudragit® L100-coated microwells: UV imaging 181 
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UV imaging experiments were performed in order to gain further information regarding the biorelevant release behavior 182 
of ASSF from Eudragit-coated microwells. Imaging was performed using a Sirius SDI UV imaging system (Sirius 183 
Analytical, East Sussex, UK), equipped with a pulsed xenon lamp as a light source and a quartz flow cell with a light 184 
path of 4 mm (CADISS-3). A 280 nm single wavelength filter was utilized for selection of detection wavelength. The 185 
total area available for imaging was 9 mm x 7 mm (1280 x 1024 pixels). A syringe pump was used for infusion of 186 
biorelevant gastric and intestinal media at a constant flow rate of 0.2 mL/min, and experiments were carried out at 187 
ambient temperature (23-25°C). Images were recorded at a rate of 2.78 frames/s, and were analyzed with Actipix D100 188 
software version 1.4 (Paraytec Ltd.) with a 10 x 1 horizontal pixel binning. 189 
 190 
In order to perform the release experiments, dark images (lamp off, 10 s duration) and reference images (lamp on, also 191 
10 s total duration) were recorded with the flow cell filled with simulated gastric medium, and with an empty stainless 192 
steel cylinder positioned in the compact holder. Data collection was then initiated and allowed to proceed for 60 s. 193 
Following this period, data recording was paused, the empty stainless steel cylinder was removed, and a cylinder fitted 194 
with a microwell chip section was inserted. A flow of gastric medium was then initiated and simultaneously data 195 
collection was recommenced. After a period of 5 min, data recording was again paused, and the syringe pump was 196 
refitted with a syringe containing biorelevant intestinal medium. Medium flow and data collection were recommenced, 197 
and were continued for a further 15 min. Experiments were performed in triplicate.  198 
 199 
3 Results and Discussion 200 
The PLLA microwells in this work were fabricated using hot embossing with a nickel stamp. The fabricated microwells 201 
exhibited a uniform surface and proved to be easy to dissociate from the stamp.  202 
 203 
The fabrication process itself resulted in the formation of microwells set into the PLLA layer on full wafer scale (Fig 2). 204 
The microwells had an outer diameter of 300 µm and an inner diameter of 240 µm. The wall height of produced 205 
microwells was 65 µm, giving a total outer height of 100 µm. These dimensions ensure that the microwells are small 206 
enough to have a good contact with the intestinal wall, but they are too large to be prone to endocytosis. In the 207 
literature, it has been reported when testing microdevices with similar dimensions on Caco-2 cells that an interaction 208 
between the microdevices and the in vitro intestinal cell line was found (Chirra et al. 2014). Furthermore, it has been 209 
shown that microdevices with a similar diameter can stabilize amorphous forms of drug and avoid recrystallization as 210 
seen for amorphous forms without any confinement (Nielsen et al. 2012). It is found that the larger surface area of the 211 
microwells will enable large contact area with the intestinal epithelium if compared with spherical microparticles. This 212 
will be an advantage of the microwells and ensure suitable conditions for interactions between the microwells and the 213 
intestinal membrane in an in vivo situation. 214 
  215 
A simplified version of a screen-printing technique was employed for filling of the microwells with ASSF, the 216 
formation of which was confirmed by XRPD (data not shown). A representative example of a drug-filled microwell is 217 
shown in Fig 3, clearly illustrating that the process resulted in complete filling of microwells and a negligible 218 
distribution of drug on the edge of the well. Methods utilized to date for drug filling of micro devices (i.e., 219 
microspotting and injection) have been limited to use in conjunction with aqueous drug solutions, and ideally with 220 
aqueous solutions containing 15-25 v/v% water-soluble polymer (Marizza et al. 2013). The use of such filling methods 221 
and conditions is time consuming, unsuitable for poorly water-soluble drugs, and furthermore impractical for large-222 
scale filling of micro devices (Ahmed et al. 2002; Marizza et al. 2013). In contrast, the modified screen printing 223 
technique presented here constitutes a method where drug can be filled into devices in a relatively short time period, 224 
and can also be utilized for various types of drugs and drug formulations without the requirement for water solubility.  225 
 226 
For the majority of orally-administered drugs the main site of drug absorption is the upper part of the small intestine 227 
(only a few drugs show appreciable absorption through the stomach or colon) (Maher et al. 2008). Simulated gastric and 228 
intestinal media have been utilized in these in vitro studies to be as close to the in vivo situation as possible. 229 
Furthermore, it is known from the literature that the simulated media have an effect on the dissolution rate of ASSF 230 
compared to buffer, and therefore it is important in this situation to use the physiologically relevant media (Nielsen et 231 
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al. 2013a). Controlled drug delivery systems which prevent release in the gastric environment but facilitate its 232 
occurrence in the absorptive upper small intestinal region are therefore desirable, in order to provide for maximal oral 233 
drug bioavailability (Kleberg et al. 2010). In the current work, drug-filled microwells were spray coated with a layer of 234 
Eudragit® L100 in order to provide such drug protection and controlled release, and additionally to maximize drug 235 
retention within microwells until the absorptive environment of the small intestine was reached. Fig 4 illustrates the 236 
appearance of drug-filled microwells after coating with Eudragit® L100. The layer was found to be 7.5±0.7 µm 237 
(n=3±SD) thick, with consistent thickness over the entire chip area.  238 
 239 
With respect to biorelevant characterization of drug release from the coated, drug-filled microwells, µ-Diss profiler 240 
experiments demonstrated an absence of release in simulated gastric medium at pH 1.6 for 120 min (Fig 5). A rapid 241 
drug release and accompanying dissolution was however seen following a change to simulated intestinal medium (pH 242 
6.5), with 96% of the initially incorporated ASSF being released and dissolved within the 180 min period of exposure to 243 
such medium (Fig 5). The rapid release and dissolution of ASSF following the pH shift was expected given that 244 
Eudragit® L100 is known to dissolve above pH 6. Also, ASSF has been shown to have a very high dissolution rate in 245 
biorelevant intestinal medium (Nielsen et al. 2013a). The µ-Diss profiler results therefore show that the Eudragit® 246 
coating is sufficiently thick to serve as an effective lid for the microwells, protecting the drug from being released at pH 247 
1.6, but providing no hindrance to a fast drug release at pH 6.5. This can be considered to translate to an effective 248 
protection of the drug by the Eudragit® coating together with the microwells in harsh conditions approximating those of 249 
the stomach, and to provide a controlled delivery of drug in an environment similar to that of the small intestine, 250 
allowing for effective drug absorption in vivo. With respect to furosemide, where a fast release is desirable, Eudragit® 251 
L100 constitutes an ideal candidate for microwell coating. In the case of other drug candidates where a prolonged 252 
release may be required, alternative polymers may be used as coating agents.  253 
 254 
In order to support the release results obtained using the µ-Diss Profiler, flow through dissolution of ASSF from filled 255 
Eudragit®-coated microwells was studied in conjunction with UV imaging. UV imaging has earlier been shown to 256 
provide useful information regarding drug dissolution processes (Boetker et al. 2011; Ostergaard et al. 2014; Ostergaard 257 
et al. 2010), and further serves as an excellent visualization method of the dissolution of furosemide in biorelevant 258 
media (Gordon et al. 2013; Nielsen et al. 2013b). In the current work, UV imaging was employed to visualize the 259 
release and dissolution of ASSF from Eudragit® L100-coated microwells on a compressed timescale compared to the 260 
release studies conducted using a µ-Diss profiler. UV imaging experiments demonstrated the same trend as that seen in 261 
µ-Diss profiler release studies. An absence of drug release and dissolution was noted in the gastric medium, with only a 262 
background level of absorbance evident in the absorbance maps (Fig 6A). An appreciable release of ASSF from the 263 
coated microwells could however already be observed 1 min following a switch of flow through dissolution medium to 264 
simulated intestinal medium and a re-equilibration of the dissolution cell (Fig 6B). This release was observed to 265 
increase (increased intensity of absorbance maps), after 5 min of exposure of microwells to a flow of biorelevant 266 
intestinal medium (Fig 6C). After 15 min of medium exposure the intensity of absorbance was noted to be decreasing 267 
(Fig 6D); this is likely due to an almost complete release of ASSF from the microwells, again reflecting the fact that 268 
ASSF has a fast dissolution rate at intestinal pH (Nielsen et al. 2013a; Nielsen et al. 2013b). 269 
 270 
4 Conclusion 271 
Microwells consisting of the biodegradable polymer PLLA were successfully fabricated using a hot embossing process. 272 
Produced microwells had an inner diameter of 240 µm and a depth of 100 µm. It was possible to fill the microwells 273 
with ASSF using a screen printing technique which proved to be both effective and accurate in microwell filling, 274 
resulting in a minimal amount of drug being deposited around the edges of or external to the microwells. The developed 275 
technique is suggested to be a method that can be utilized for filling of all types of powder drug into micro devices. 276 
After coating of a Eudragit® L100 layer on the cavity of drug-filled microwells, drug release was studied using a µ-Diss 277 
profiler as well as a UV imaging system in conjunction with biorelevant release media. Release experiments conducted 278 
using both techniques showed that the Eudragit® layer prevented drug release from microwells in biorelevant gastric 279 
medium, while an immediate release of the ASSF was seen in biorelevant intestinal medium.  The developed Eudragit®-280 
coated microwells therefore provide an effective drug protection and prevention of release in a gastric environment, 281 
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while allowing for rapid release in conditions approximating those of the small intestine. The fabricated PLLA 282 
microwells therefore show the ability to facilitate effective oral absorption of incorporated drug, demonstrating their 283 
significant future potential as oral drug delivery systems.  284 
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Figures and captions 328 
 329 
 330 
 331 
Fig 1 Schematic drawing of the concept of the microwells as an oral drug delivery system: a) the biodegradable 332 
microwells fabricated from PLLA, b) filled with ASSF c) and subsequently spray coated with a lid of Eudragit® L100. 333 
d) at pH 6.5 (intestinal pH) ASSF is released from the microwells  334 
  335 
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 336 
 337 
 338 
Fig 2 Graphical representation of the powder filling process of PLLA microwells using a modified screen printing 339 
process. 1. The fabricated stencil mask is aligned to the microwells. 2-3. ASSF is pressed into the microwells. 4. The 340 
stencil is removed, leaving PLLA microwells filled with powder drug 341 
  342 
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 343 
 344 
Fig 3 SEM image of a single microwell fabricated in PLLA by hot embossing 345 
  346 
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 347 
 348 
Fig 4 Representative optical microscope images (top view) of a PLLA microwell filled with ASSF 349 
  350 
b) 
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 351 
 352 
Fig 5 A SEM image of drug-filled PLLA microwells spray coated with Eudragit® L-100 353 
  354 
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 355 
Fig 6 Release profiles obtained from PLLA microwells filled with ASSF and coated with Eudragit® L100 in biorelevant 356 
gastric medium pH 1.6 (0-120 min) and biorelevant intestinal medium pH 6.5 (120-300 min). Data shown represent the 357 
mean of three replicates±SD 358 
  359 
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 360 
 361 
Fig 7 Representative UV absorbance maps at 280 nm showing the release of ASSF from Eudragit® L100-coated PLLA 362 
microwells in a) simulated gastric medium (pH 1.6) after 5 min, and in simulated intestinal medium (pH 6.5) after b) 1 363 
min, c) 5 min and d) 15 min. The contour lines correspond to absorbance values of: dark blue = 100 mAU, green = 150 364 
mAU, orange = 200 mAU, light blue = 250 mAU, and brown = 300 mAU 365 
 366 
After 5 min in gastric media Intestinal Media – 1 min
Intestinal Media – 5 min Intestinal Media – 15 min
A) B)
C) D)
